JinkoSolar's Main Operating Unit Estimates Nine-Month Net Loss Of RMB2.98 Billion To RMB3.58 Billion
Excluding extraordinary items, the estimated loss widens to RMB3,811.12 million to RMB4,411.12 million, under PRC accounting rules.
Jinko Solar Co., the principal operating subsidiary of JinkoSolar, estimates a net loss attributable to its shareholders of RMB2,976.33 million to RMB3,576.33 million for the nine months ended September 30, 2026. JinkoSolar relayed the preliminary, unaudited range in a release dated Friday, furnished to the SEC on Form 6-K.
What the release says
The subsidiary, which the release calls Jiangxi Jinko, published the estimates itself, and JinkoSolar said in its statement that it had relayed them. The company's release gives its stock symbol on the SSE as 688223.
A second range strips out extraordinary gains and losses. On that basis, the estimated net loss attributable to Jiangxi Jinko shareholders is RMB3,811.12 million to RMB4,411.12 million, a bigger loss than the headline range.
Both figures are in renminbi and cover only the nine-month period. The release gives no comparison period.
Why these are not JinkoSolar's own numbers
The Jiangxi Jinko figures follow PRC GAAP, China's accounting standards. JinkoSolar's consolidated results follow U.S. accounting principles, and they also include JinkoSolar and its other subsidiaries.
Because of those two differences, the company said investors should exercise caution with the subsidiary's estimates. It advised them not to base investment decisions solely on the preliminary figures.
JinkoSolar owns approximately 54.32% of Jiangxi Jinko. If you hold the U.S.-listed JKS shares, the subsidiary's loss is only part of what feeds into the consolidated results.
The stock
JKS shares closed at $8.12 on Friday, down 2.87% from $8.36 at Thursday's close. The company's market value was $438 million at that close.
The company's release describes over 10 production facilities worldwide as of June 30, 2026, but gives no date for JinkoSolar's own consolidated nine-month results.